Adjuvant Trials

1. Chemotherapy With or Without Bevacizumab in Treating Patients with Stage IB, Stage II, or Stage IIIA Non-Small Cell Lung Cancer That Was Removed By Surgery

This study is ongoing, but not recruiting participants.
 
ClinicalTrials.gov Identifier: NCT00324805

This randomized phase III trial is studying chemotherapy and bevacizumab to see how well they work compared to chemotherapy alone in treating patients with stage IB, stage II, or stage IIIA non-small cell lung cancer that was removed by surgery.
Quebec
Hospital Charles Lemoyne, Greenfield Park
McGill Cancer Centre at McGill University, Montreal

Saskatchewan
Allan Blair Cancer Centre at Pasqua Hospital, Regina
Saskatoon Cancer Centre at the University of Saskatchewan, Saskatoon

Alberta
Cross Cancer Institute, Edmonton

Manitoba
Cancer Care Manitoba, Winnipeg

New Brunswick
Moncton Hospital, Moncton

Nova Scotia
Cancer Care NS, Halifax

Ontario
Princess Margaret Hospital, Toronto
London regional Cancer Center, London
Algoma District Cancer Program at Sault Area Hospital, Sault Ste Marie
Northeastern Ontario Regional Cancer Centre, Sudbury
Cancer Care Program at Thunder Bay Regional Health Sciences, Thunder Bay
Ottawa Regional Cancer Program, Ottawa
Royal Victoria Hospital, Barrie
Trillium Health Center, Toronto

British Columbia
BCCA, Vancouver Centre

2. Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC

This study is currently recruiting participants.
 
ClinicalTrials.gov Identifier: NCT02273375

The purpose of this study is to find out whether it is better to receive a new drug, MEDI4736, or better to receive no further treatment after surgery (and possibly chemotherapy) for lung cancer.
Newfoundland
Dr. H. Bliss Murphy Cancer Centre, St. John's

Ontario
Juravinski Cancer Centre, Hamilton
Cancer Centre of Southeastern Ontario, Kingston
Lakeridge Health, Oshawa
Ottawa Hospital Research Institute, Ottawa
Algoma District Cancer Program, Sault Ste. Marie
Niagara Health System, St. Catharines
Health Sciences North, Sudbury
Thunder Bay Regional Health Science Centre, Thunder Bay
Mount Sinai Hospital, Toronto
Princess Margaret Hospital, Toronto

Quebec
McGill University, Montreal

Saskatchewan
Allan Blair Cancer Centre, Regina
Saskatoon Cancer Centre, Saskatoon

Alberta
Cross Cancer Institute, Edmonton
Tom Baker Cancer Center, Calgary

Nova Scotia
QE II Health Sciences Center, Halifax

3. A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer(PACIFIC)

This study is ongoing, but not recruiting participants.
 
ClinicalTrials.gov Identifier: NCT02125461

Phase III, Randomised, Double-blind, Placebo-controlled, Multi-centre, International Study of MEDI4736 as Sequential Therapy in Patients With Locally Advanced, Unresectable Non-Small CellLung Cancer (Stage III) Who Have Not Progressed Following Definitive, Platinum-based, Concurrent Chemoradiation Therapy (PACIFIC)
Alberta
Calgary
Edmonton

Ontario
Barrie
London
Newmarket

British Columbia
Vancouver

4. AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy (ADAURA)

ClinicalTrials.gov Identifier: NCT02511106

A Phase III, Double-blind, Randomized, Placebo-controlled Multi-centre, Study to Assess the Efficacy and Safety of AZD9291 Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy (ADAURA)
New Brunswick
Moncton

Ontario
Brampton